Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Loxo Oncology, Inc.
Scientific Title
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors